TrialBMC cancer2014

Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.

Jean-Pascal H Machiels et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.